EPHA5 and lung carcinoma: That ∼70% of lung cancer specimens analyzed in this study expressed EphA5 and that EphA5 expression in normal tissues is largely restricted to the developing central nervous system render EphA5 a suitable target for the development of systemic treatments, such as a monoclonal antibody-based targeted therapy.